18.08.2016

Petrovax Pharm started shipping Grippol® plus vaccine for influenza prevention in children within the framework of the Russian National Immunization Schedule (RNIS). Through the end of October, all Russia’s regions will receive more than 8.5 m Grippol® plus doses.

In 2016, the children population is being covered with flu vaccine Grippol® plus within the RNIS framework under the agreement with National Immunobiological Company OJSC that has been appointed the sole vendor pursuant to the Russian Government Resolution No. 1125-r of  17.06.2015 . The two companies signed a relevant agreement on  12.08.2016 , and already in August, Petrovax Pharm would supply 5 m vaccine doses to Russia’s regions.

Petrovax Pharm is the Russian largest vaccine manufacturer, with more than 20 m doses of flu vaccine, and more than 4.5 m doses of pneumococcal vaccine a year.

Vaccine background information

Grippol® plus is the only Russian subunit adjuvanted inactivated influenza vaccine with high efficacy and safety than have been proved by  many-year experience of mass use for flu prevention in adults and children. This vaccine is  preservative-free , and is manufactured in disposable syringes at a state- of-the-art facility to Russian and international GMP standards. Since 2009, the vaccine has been supplied within the framework of the Russian National Immunization Schedule for children aged 6+ months, and pregnant women.

Every year, the vaccine formula is updated pursuant to the WHO guidelines for a specific epidemic season. Grippol® plus is produced from local ingredients only, including antigens.


Back to the list